Here are three things to know.
1. J&J’s diabetes care business consists of LifeScan, which produces blood glucose monitors, and Animas and Calibra Medical, which manufacture insulin delivery devices.
2. The drugmaker said it was considering options, including divestiture, for its diabetes companies last January. In October, Johnson & Johnson shared plans to shut down Animas’ operations in the U.S. and Canada after failing to find a buyer.
3. Several Chinese healthcare companies are interested in acquiring Calibra Medical and LifeScan from J&J, according to inside sources.
“The evaluation of potential strategic options for LifeScan and Calibra Medical Inc. is ongoing and we do not have an announcement regarding these businesses at this time,” J&J told Reuters.
More articles on supply chain:
Mylan reaffirms $1B share buyback plan
Dr. Reddy’s recalls 1k cancer drug vials over container defect: 4 things to know
6 must-reads for supply chain leaders
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.